FOR IMMEDIATE RELEASE

Contact:
Luanne Rodgers
Organ Recovery Systems
847-824-2600
lrodgers@organ-recovery.com

Chris Stamm or Amy Kramer
Schwartz Communications, Inc.
781-684-0770
ors@schwartz-pr.com

Matt Mundo
The Rosen Group Public Re
212-255-8455 x 24;
matt@rosengrouppr.com

ORGAN RECOVERY SYSTEMS CEO DAVID KRAVITZ NAMED ONE OF FAST COMPANY MAGAZINE'S FAST 50 CHAMPIONS OF INNOVATION

CHICAGO, Ill.—Tuesday, February 17—Today, Organ Recovery Systems, a developer of technologies to improve the quality and quantity of transplantable organs, tissues and cells, announced founder and CEO David Kravitz has been named to *Fast Company* magazine's third annual list of "Fast 50" innovators –individuals whose achievements have significantly advanced their companies or industries.

The Fast 50 will appear in the March issue of *Fast Company*, the nation's leading magazine for management innovators, hitting newsstands on February 18. The list includes 50 exceptional achievers selected from online submissions by *Fast Company* readers. This year's list was selected from more than 1,650 entries submitted by individuals in 30 countries and nearly every state in the union. The complete list of the Fast 50 begins on page 79 of *Fast Company*. Profiles of the Fast 50, as well as all reader submissions, may be accessed online at the special Fast 50 Website at www.fastcompany.com/fast50

"The Fast 50 are the idea elite of business, individuals with the vision and personal commitment to propel their companies and industries into the future," said *Fast Company* editor-in-chief John Byrne.

Selected by *Fast Company* editors, the Fast 50 includes executives, activists, marketers, designers, scientists, engineers and other leaders from a variety of backgrounds. Some are solo entrepreneurs and researchers. Others come from a wide range of organizations – from large corporations to start-ups.

Kravitz, named as a Rising Star on this year's Fast 50 list, founded Organ Recovery Systems in 1998 and in just five years, guided the company through the development and FDA clearance of its flagship product, the LifePort™ Kidney Transporter. Created to address the critical shortage of transplantable organs, the LifePort Kidney Transporter provides a new high-tech alternative to the

- More -

conventional static method of organ storage and transportation—a cooler filled with ice. Using the process of perfusion—the passing of chemical solutions through organs to minimize tissue damage—the device gives transplant surgeons more time to transport the organs, ensuring a proper match between donor and recipient. Machine perfusion with the LifePort Kidney Transporter holds the promise of increasing the organ pool and improving outcomes. Perfusion has the potential to enable the use of more kidneys and to reduce the number of discarded kidneys. A retrospective review of US kidney transplant data indicates that perfused kidneys function better after transplant than statically stored kidneys. If perfusion was the standard of care nationwide, the resulting combination of more organs and improved outcomes could save the healthcare system more than $1 billion annually.

"Being named to *Fast Company*'s list of champions of innovation not only gives credence to the direction and momentum of Organ Recovery Systems, but also recognizes the work of our entire team," Kravitz remarked. "Organ Recovery Systems is dedicated to enhancing the LifePort platform to introduce new, life-saving devices for the transplant community and plans to be a champion of innovation for years to come."

About Fast Company
Founded in 1996 and published monthly, New York-based *Fast Company* (www.fastcompany.com) covers ideas, trends and individuals devoted to innovation and managing change in today's economy. The magazine is owned by Gruner + Jahr USA, one of the top-ranked magazine publishers in the U.S., reaching one of the largest readerships in America. Gruner + Jahr USA also publishes Inc, Child, Family Circle, Fitness, Parents and YM.

About Organ Recovery Systems
Organ Recovery Systems is a privately held company developing technologies and services to improve the quality and quantity of organs, tissues, and cells for transplantation. The company's flagship medical device, the FDA-cleared LifePort™ Kidney Transporter, is a mobile perfusion device that establishes a continuum of organ care spanning the critical time between recovery and transplantation. LifePort devices for the heart, liver and pancreas are in development, and the company is creating methods to improve the preservation and assessment of donated pancreas for improved yield and quality of Islet cells for transplant. The LifePort was named one of the top 100 breakthrough technologies by *Popular Science* in its 2003 Best of What's New Awards.

Organ Recovery Systems is organized into three operating groups: the Perfusion Services Group helps transplant centers and organ procurement organizations (OPOs) by employing proprietary perfusion techniques for evaluation and therapy of traditional, expanded criteria, and nonheartbeating donor kidneys prior to transplant; the Medical Devices Group develops perfusion-based devices to improve the preservation, assessment, and treatment of organs for transplantation; and the Charleston Research Center develops new technologies for cell and tissue preservation and evaluation while conducting basic and applied research to support the company's platform of organ therapy products. For more about Organ Recovery Systems visit http://www.organ-recovery.com.

###